Curasight A/S
A clinical-stage biotech developing a theranostic platform for cancer diagnosis and treatment.
CURAS | SPGR
Overview
Corporate Details
- ISIN(s):
- DK0061295797 (+3 more)
- LEI:
- 984500C9E3ADR98F1070
- Country:
- Denmark
- Address:
- Ole Maaløes Vej 3, 2200 København N
- Website:
- https://www.curasight.com/
- Sector:
- Manufacturing
Description
Curasight A/S is a clinical-stage biotechnology company focused on improving the diagnosis and treatment of various cancers. The company is developing a novel theranostic platform targeting the urokinase-type plasminogen activator receptor (uPAR), a biomarker for cancer aggressiveness. This platform integrates two main components: uTRACE®, a diagnostic agent for precise Positron Emission Tomography (PET) imaging, and uTREAT®, a targeted radionuclide therapy. The uTRACE® diagnostic identifies patients with uPAR-positive tumors, enabling subsequent treatment with uTREAT®. This approach aims to deliver radiation directly to cancer cells, minimizing exposure to healthy tissue and providing a more gentle and efficient therapeutic option. The company's technology is being advanced through multiple phase II clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Curasight A/S filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Curasight A/S
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Curasight A/S via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||